Israeli firm NeuroKaire has commercialized a laboratory-developed test that assesses major depressive disorder through analysis of patient-derived frontal cortical neurons differentiated from induced pluripotent stem cells. The test exposes these neurons to multiple antidepressants, quantifying connectivity changes to predict patient-specific drug response. Complemented by pharmacogenetics and AI-driven image analysis, this approach enables faster, personalized treatment selection compared to current trial-and-error prescribing practices. Early multisite clinical validation showed concordance with real-world patient responses, with plans for expanded prospective trials.